Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 21, 2025
Daily News
April 21, 2025
- Diabetes Society Flags DKA Risk for AstraZeneca’s Truqap after Report of Death
April 21, 2025
- Celltrion, Nippon Kayaku to Unify Remicade/Herceptin Biosimilars
April 21, 2025
- CSL’s New HAE Drug Andembry Now Available in Japan
April 21, 2025
- Ruling Coalition Wary of Scrapping Coverage for OTC-Like Drugs
April 21, 2025
- Diuretic, Hypertension Drugs, Zolgensma under PMDA Risk Review
April 21, 2025
- Nippon Shinyaku’s EGPA Drug Gets Orphan Tag in US
April 21, 2025
- Chugai’s DMD Gene Therapy Now in Line for Conditional Approval
April 21, 2025
- Lower House Passes Bill to Amend PMD Act
April 21, 2025
- MOF Tells LDP Members Govt Can Address Inflation with Current Budget Policy
April 21, 2025
- Meiji/KM Biologics Change Target Strain of Investigational COVID Jab
April 21, 2025
- Eye Drop for Myopia Control Enters PII Study in Japan: Rohto
April 21, 2025
- iPSC-Derived Cells Effective in Parkinson’s, Approval Could Come in FY2025
April 21, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…